Patents Assigned to LIQMEDS WORLDWIDE LIMITED
-
Patent number: 11975006Abstract: The present disclosure is directed to pharmaceutical compositions comprising a PDE V inhibitor and one or more pharmaceutical excipients or additives wherein the pharmaceutical compositions are in the form of liquid pharmaceutical compositions. The pharmaceutical compositions of the present disclosure are useful for the treatment of diseases or conditions which are treatable by administration of PDE V inhibitor drug such as pulmonary arterial hypertension, erectile dysfunction, etc.Type: GrantFiled: April 28, 2023Date of Patent: May 7, 2024Assignee: LIQMEDS WORLDWIDE LIMITEDInventors: Jinal Pandya, Sandip P. Mehta, Manish Umrethia, Jayanta Kumar Mandal, Hiren Pansuriya
-
Patent number: 11931455Abstract: Disclosed herein are pharmaceutical compositions in the form of a suspension for oral delivery. Some embodiments provide a pharmaceutical composition in the form of a suspension for oral delivery comprising an active pharmaceutical ingredient; water; a suspending agent; a buffering agent; and one or more of a wetting agent and a binder/filler. In some embodiments, the active pharmaceutical ingredient is selected from quetiapine, sildenafil, tadalafil, cinacalcet, ticagrelor, mycophenolate, aprepitant, zonisamide, and primidone.Type: GrantFiled: July 31, 2023Date of Patent: March 19, 2024Assignee: LIQMEDS WORLDWIDE LIMITEDInventors: Sandip Mehta, Manish Kumar Umrethia, Jayanta Mandal
-
Patent number: 11925704Abstract: The present invention provides liquid oral dosage form of lipid lowering agent suitable for oral administration to human or animals.Type: GrantFiled: April 14, 2023Date of Patent: March 12, 2024Assignee: LIQMEDS WORLDWIDE LIMITEDInventors: Sandip P. Mehta, Henil Alpeshbhai Patel, Jayanta Kumar Mandal
-
Patent number: 11918684Abstract: The present invention provides pharmaceutical composition of immunosuppressive agent in oral suspension dosage form. The oral suspension composition comprises of immunosuppressive agent with other pharmaceutical excipients such as vehicle, suspending agent, solvent or cosolvent, preservative, sweetener, antifoaming agent, wetting agent, buffering agent and flavouring agent. The present invention oral suspension having improved stability, palatability with high dose of active ingredient. The present invention provides oral suspension with flavor that has masked bitter taste of the drug and eliminates difficulty of administration. Further, the present invention also provides a convenient, easy process for preparation thereof.Type: GrantFiled: March 12, 2018Date of Patent: March 5, 2024Assignee: LIQMEDS WORLDWIDE LIMITEDInventors: Sandip Mehta, Manish Umrethia, Henil Patel, Jayanta Kumar Mandal
-
Publication number: 20230381187Abstract: The present disclosure is directed to pharmaceutical compositions comprising sildenafil or a pharmaceutically acceptable salt thereof and one or more pharmaceutical excipients or additives wherein the pharmaceutical compositions are in the form of liquid pharmaceutical compositions. The pharmaceutical compositions of the present disclosure are useful for the treatment of diseases or conditions which are treatable by administration of sildenafil or a pharmaceutically acceptable salt thereof such as pulmonary arterial hypertension, erectile dysfunction, etc.Type: ApplicationFiled: August 4, 2023Publication date: November 30, 2023Applicant: LIQMEDS WORLDWIDE LIMITEDInventors: Jinal PANDYA, Sandip P. MEHTA, Manish UMRETHIA, Jayanta Kumar MANDAL, Hiren PANSURIYA
-
Patent number: 11759468Abstract: The present disclosure is directed to pharmaceutical compositions comprising sildenafil or a pharmaceutically acceptable salt thereof and one or more pharmaceutical excipients or additives wherein the pharmaceutical compositions are in the form of liquid pharmaceutical compositions. The pharmaceutical compositions of the present disclosure are useful for the treatment of diseases or conditions which are treatable by administration of sildenafil or a pharmaceutically acceptable salt thereof such as pulmonary arterial hypertension, erectile dysfunction, etc.Type: GrantFiled: August 31, 2022Date of Patent: September 19, 2023Assignee: LIQMEDS WORLDWIDE LIMITEDInventors: Jinal Pandya, Sandip P. Mehta, Manish Umrethia, Jayanta Kumar Mandal, Hiren Pansuriya
-
Publication number: 20230285398Abstract: The present disclosure is directed to pharmaceutical compositions comprising a PDE V inhibitor and one or more pharmaceutical excipients or additives wherein the pharmaceutical compositions are in the form of liquid pharmaceutical compositions. The pharmaceutical compositions of the present disclosure are useful for the treatment of diseases or conditions which are treatable by administration of PDE V inhibitor drug such as pulmonary arterial hypertension, erectile dysfunction, etc.Type: ApplicationFiled: April 28, 2023Publication date: September 14, 2023Applicant: LiqMeds Worldwide LimitedInventors: Jinal PANDYA, Sandip P. MEHTA, Manish UMRETHIA, Jayanta Kumar MANDAL, Hiren PANSURIYA
-
Patent number: 11723866Abstract: Disclosed herein is a liquid pharmaceutical formulation substantially free of water, comprising: (i) amlodipine or a pharmaceutically acceptable salt thereof, (ii) at least one pharmaceutically acceptable excipient, and (iii) a sufficient amount of a vehicle comprising glycerin. Also disclosed herein is a liquid pharmaceutical formulation substantially free of water and ethanol, comprising: (i) amlodipine or a pharmaceutically acceptable salt thereof, (ii) at least one pharmaceutically acceptable excipient, and (iii) a sufficient amount of a vehicle comprising glycerin.Type: GrantFiled: June 15, 2022Date of Patent: August 15, 2023Assignee: LIQMEDS WORLDWIDE LIMITEDInventors: Jayanta Kumar Mandal, Malay Patel, Swati Nagar, Michael Paul DeHart
-
Publication number: 20230248645Abstract: The present invention provides liquid oral dosage form of lipid lowering agent suitable for oral administration to human or animals.Type: ApplicationFiled: April 14, 2023Publication date: August 10, 2023Applicant: LIQMEDS WORLDWIDE LIMITEDInventors: Sandip P. MEHTA, Henil Alpeshbhai PATEL, Jayanta Kumar MANDAL
-
Patent number: 11666576Abstract: The present disclosure is directed to pharmaceutical compositions comprising a PDE V inhibitor and one or more pharmaceutical excipients or additives wherein the pharmaceutical compositions are in the form of liquid pharmaceutical compositions. The pharmaceutical compositions of the present disclosure are useful for the treatment of diseases or conditions which are treatable by administration of PDE V inhibitor drug such as pulmonary arterial hypertension, erectile dysfunction, etc.Type: GrantFiled: June 6, 2022Date of Patent: June 6, 2023Assignee: LIQMEDS WORLDWIDE LIMITEDInventors: Jinal Pandya, Sandip P. Mehta, Manish Umrethia, Jayanta Kumar Mandal, Hiren Pansuriya
-
Patent number: 11654106Abstract: The present invention provides liquid oral dosage form of lipid lowering agent suitable for oral administration to human or animals.Type: GrantFiled: May 26, 2022Date of Patent: May 23, 2023Assignee: LIQMEDS WORLDWIDE LIMITEDInventors: Sandip P. Mehta, Henil Alpeshbhai Patel, Jayanta Kumar Mandal
-
Publication number: 20230059869Abstract: Disclosed herein is an oral pharmaceutical solution, comprising: about 0.5 mg/mL to about 120 mg/mL of clopidogrel or a pharmaceutically acceptable salt thereof; about 35 mg/mL to about 200 mg/mL propylene glycol; one or more pharmaceutically acceptable excipients; and a vehicle comprising glycerin; wherein the oral pharmaceutical solution has an amount of water of less than or equal to 5% w/w and an amount of ethanol less than or equal to 6% w/w. Oral pharmaceutical solution disclosed herein have a clopidogrel content of 100±10% when stored for about 24 months at 25° C.±2° C. and 60±5% relative humidity.Type: ApplicationFiled: August 3, 2022Publication date: February 23, 2023Applicant: LIQMEDS WORLDWIDE LIMITEDInventors: Jayanta Kumar MANDAL, Malay PATEL, Swati NAGAR
-
Publication number: 20220409621Abstract: The present disclosure is directed to pharmaceutical compositions comprising sildenafil or a pharmaceutically acceptable salt thereof and one or more pharmaceutical excipients or additives wherein the pharmaceutical compositions are in the form of liquid pharmaceutical compositions. The pharmaceutical compositions of the present disclosure are useful for the treatment of diseases or conditions which are treatable by administration of sildenafil or a pharmaceutically acceptable salt thereof such as pulmonary arterial hypertension, erectile dysfunction, etc.Type: ApplicationFiled: August 31, 2022Publication date: December 29, 2022Applicant: LIQMEDS WORLDWIDE LIMITEDInventors: Jinal PANDYA, Sandip P. MEHTA, Manish UMRETHIA, Jayanta Kumar MANDAL, Hiren PANSURIYA
-
Patent number: 11464778Abstract: The present disclosure is directed to pharmaceutical compositions comprising a PDE V inhibitor and one or more pharmaceutical excipients or additives wherein the pharmaceutical compositions are in the form of liquid pharmaceutical compositions. The pharmaceutical compositions of the present disclosure are useful for the treatment of diseases or conditions which are treatable by administration of PDE V inhibitor drug such as pulmonary arterial hypertension, erectile dysfunction, etc.Type: GrantFiled: December 24, 2018Date of Patent: October 11, 2022Assignee: LIQMEDS WORLDWIDE LIMITEDInventors: Jinal Pandya, Sandip P. Mehta, Manish Umrethia, Jayanta Kumar Mandal, Hiren Pansuriya
-
Patent number: 11458095Abstract: Disclosed herein is a liquid pharmaceutical formulation substantially free of water, comprising: (i) amlodipine or a pharmaceutically acceptable salt thereof, (ii) at least one pharmaceutically acceptable excipient, and (iii) a sufficient amount of a vehicle comprising glycerin. Also disclosed herein is a liquid pharmaceutical formulation substantially free of water and ethanol, comprising: (i) amlodipine or a pharmaceutically acceptable salt thereof, (ii) at least one pharmaceutically acceptable excipient, and (iii) a sufficient amount of a vehicle comprising glycerin.Type: GrantFiled: January 14, 2022Date of Patent: October 4, 2022Assignee: LIQMEDS WORLDWIDE LIMITEDInventors: Jayanta Kumar Mandal, Malay Patel, Swati Nagar, Michael Paul DeHart
-
Publication number: 20220280421Abstract: The present invention provides liquid oral dosage form of lipid lowering agent suitable for oral administration to human or animals.Type: ApplicationFiled: May 26, 2022Publication date: September 8, 2022Applicant: LIQMEDS WORLDWIDE LIMITEDInventors: Sandip P. MEHTA, Henil Alpeshbhai PATEL, Jayanta Kumar MANDAL
-
Patent number: 11382917Abstract: The present disclosure is directed to pharmaceutical compositions comprising a PDE V inhibitor and one or more pharmaceutical excipients or additives wherein the pharmaceutical compositions are in the form of liquid pharmaceutical compositions. The pharmaceutical compositions of the present disclosure are useful for the treatment of diseases or conditions which are treatable by administration of PDE V inhibitor drug such as pulmonary arterial hypertension, erectile dysfunction, etc.Type: GrantFiled: August 16, 2021Date of Patent: July 12, 2022Assignee: LIQMEDS WORLDWIDE LIMITEDInventors: Jinal Pandya, Sandip P. Mehta, Manish Umrethia, Jayanta Kumar Mandal, Hiren Pansuriya
-
Patent number: 11369567Abstract: The present invention provides liquid oral dosage form of lipid lowering agent suitable for oral administration to human or animals.Type: GrantFiled: June 7, 2017Date of Patent: June 28, 2022Assignee: LIQMEDS WORLDWIDE LIMITEDInventors: Sandip P. Mehta, Henil Alpeshbhai Patel, Jayanta Kumar Mandal
-
Patent number: 11337979Abstract: The present disclosure is directed to pharmaceutical compositions comprising a PDE V inhibitor and one or more pharmaceutical excipients or additives wherein the pharmaceutical compositions are in the form of liquid pharmaceutical compositions. The pharmaceutical compositions of the present disclosure are useful for the treatment of diseases or conditions which are treatable by administration of PDE V inhibitor drug such as pulmonary arterial hypertension, erectile dysfunction, etc.Type: GrantFiled: August 16, 2021Date of Patent: May 24, 2022Assignee: LIQMEDS WORLDWIDE LIMITEDInventors: Jinal Pandya, Sandip P. Mehta, Manish Umrethia, Jayanta Kumar Mandal, Hiren Pansuriya
-
Patent number: 11253474Abstract: Disclosed herein is a liquid pharmaceutical formulation substantially free of water, comprising: (i) amlodipine or a pharmaceutically acceptable salt thereof, (ii) at least one pharmaceutically acceptable excipient, and (iii) a sufficient amount of a vehicle comprising glycerin. Also disclosed herein is a liquid pharmaceutical formulation substantially free of water and ethanol, comprising: (i) amlodipine or a pharmaceutically acceptable salt thereof, (ii) at least one pharmaceutically acceptable excipient, and (iii) a sufficient amount of a vehicle comprising glycerin.Type: GrantFiled: February 24, 2021Date of Patent: February 22, 2022Assignee: LIQMEDS WORLDWIDE LIMITEDInventors: Jayanta Kumar Mandal, Malay Patel, Swati Nagar, Michael Paul DeHart